Transcription-translation and translation-messenger RNA decay coupling: separate mechanisms for different messengers.
Antibiotics were used to inhibit protein synthesis at specific steps in the biosynthetic pathway. In this way, it was possible to study the coupling of protein synthesis to the accumulation of biologically active mRNA in T4-infected Escherichia coli. Functional mRNA for the phage enzymes deoxynucleotide kinase (EC 2.7.4.4; ATP: nucleoside monophosphate phosphotransferase or nucleosidemonophosphate kinase) and alpha-glucosyltransferase (EC 2.4.1.5; 1, 4-alpha-D-glucan: 1, 6-alpha-D-glucan 6-alpha-glucosyltransferase or dextrin dextranase) accumulated during inhibition of protein synthesis irrespective of the step in the synthesis of protein that was blocked. Under these conditions, however, the rate of mRNA synthesis for both enzymes was significantly inhibited. In contrast, the rate of degradation of these mRNAs was markedly dependent on the step in protein synthesis that was inhibited. That is, the site for mRNase action was different for each message. The most important step in protein synthesis required for the stability of deoxynucleotide kinase mRNA is the initiation step. A single ribosome bound to the 5' end of the deoxynucleotide kinase mRNA can stabilize the molecule. On the other hand, the initiation event does not seem to be important for stabilizing the alpha-glucosyltransferase mRNA. Instead, a high ribosome denisty on the alpha-glucosyltransferase messenger is required to achieve significant stability. Therefore, in studying messenger metabolism, it is important to focus on the functional stability of specific mRNAs instead of on total messenger since each mRNA can be metabolized differently.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002701:Chloramphenicol / Q000494:pharmacology; D003090:Coliphages / Q000378:metabolism; D005672:Fusidic Acid / Q000494:pharmacology; D005964:Glucosyltransferases / Q000096:biosynthesis; D010770:Phosphotransferases / Q000096:biosynthesis; D014176:Protein Biosynthesis / Q000187:drug effects; D011691:Puromycin / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism*; D012367:RNA, Viral / Q000096:biosynthesis / Q000378:metabolism*; D012270:Ribosomes / Q000378:metabolism; D012293:Rifampin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D014764:Viral Proteins / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D012333:RNA, Messenger; D012367:RNA, Viral; D014764:Viral Proteins; D011691:Puromycin; D005672:Fusidic Acid; D002701:Chloramphenicol; D005964:Glucosyltransferases; D010770:Phosphotransferases; D013752:Tetracycline; D012293:Rifampin